The grant will support continued preclinical research on microRNA targeting in cardiovascular disease and help to establish a novel model system of chronic heart failure.
The research aims to show the potential of miRNA regulation as a novel treatment for cardiac disease.
RxGen CEO Matthew Lawrence said the combination of RxGen’s in-vivo modeling capabilities and miRagen’s microRNA research expertise uniquely positions them to accelerate cardiac applications of microRNA therapeutics.